{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:21:31Z","timestamp":1793647291050,"version":"4.5.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,9,28]]},"DOI":"10.1038\/s41416-021-01486-8","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T14:02:58Z","timestamp":1626271378000},"page":"948-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma"],"prefix":"10.1038","volume":"125","author":[{"given":"Sarah","family":"Bouchereau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Chaplain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Fort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Beauchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sidib\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Chapalain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Gonzalez-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Longvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0789","authenticated-orcid":false,"given":"Elisa","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247\u201357.","journal-title":"Eur J Cancer"},{"key":"1486_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336.","journal-title":"N Engl J Med"},{"key":"1486_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","volume":"126","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33\u201344.","journal-title":"Eur J Cancer"},{"key":"1486_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/1078-0432.CCR-18-4180","volume":"26","author":"A Ribas","year":"2020","unstructured":"Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, et al. Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin Cancer Res. 2020;26:46\u201353.","journal-title":"Clin Cancer Res"},{"key":"1486_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582\u20138.","journal-title":"Ann Oncol"},{"key":"1486_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"1486_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio M, Grob J-J, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33:1191\u20136.","journal-title":"J Clin Oncol"},{"key":"1486_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejca.2019.05.015","volume":"116","author":"S Kreft","year":"2019","unstructured":"Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, et al. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur J Cancer. 2019;116:207\u201315.","journal-title":"Eur J Cancer"},{"key":"1486_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/CMR.0000000000000131","volume":"25","author":"MS Schreuer","year":"2015","unstructured":"Schreuer MS, Chevolet IL, Jansen YJ, Seremet TC, Wilgenhof S, Li\u00e9nard D, et al. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Res. 2015;25:68\u201374.","journal-title":"Melanoma Res"},{"key":"1486_CR10","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1200\/JCO.20.00198","volume":"38","author":"R Seth","year":"2020","unstructured":"Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, et al. Systemic therapy for melanoma: ASCO Guideline. J Clin Oncol. 2020;38:3947\u201370.","journal-title":"J Clin Oncol"},{"key":"1486_CR11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239\u201351.","journal-title":"Lancet Oncol"},{"key":"1486_CR12","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326.","journal-title":"N Engl J Med"},{"key":"1486_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","volume":"13","author":"SE Park","year":"2018","unstructured":"Park SE, Lee SH, Ahn JS, Ahn M-J, Park K, Sun J-M. Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non\u2013small cell lung cancer. J Thorac Oncol. 2018;13:106\u201311.","journal-title":"J Thorac Oncol"},{"key":"1486_CR14","doi-asserted-by":"publisher","first-page":"9505","DOI":"10.1200\/JCO.2019.37.15_suppl.9505","volume":"37","author":"M Weichenthal","year":"2019","unstructured":"Weichenthal M, Ugurel S, Leiter UM, Satzger I, K\u00e4hler KC, Welzel J, et al. Salvage therapy after failure from anti-PD-1 single agent treatment: a Study by the German ADOReg melanoma registry. J Clin Oncol. 2019;37:9505\u20139505.","journal-title":"J Clin Oncol"},{"key":"1486_CR15","doi-asserted-by":"publisher","first-page":"e21329","DOI":"10.1097\/MD.0000000000021329","volume":"99","author":"M Saint-Jean","year":"2020","unstructured":"Saint-Jean M, Fronteau C, Peuvrel L, Khammari A, Varey E, Qu\u00e9reux G, et al. Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients. Medicine. 2020;99:e21329.","journal-title":"Medicine"},{"key":"1486_CR16","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 2018;25:2105\u201310.","journal-title":"Ann Surg Oncol"},{"key":"1486_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1486_CR18","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu W-J, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510\u20137.","journal-title":"J Clin Oncol"},{"key":"1486_CR19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association.","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"1486_CR20","doi-asserted-by":"publisher","first-page":"e21588","DOI":"10.1200\/JCO.2018.36.15_suppl.e21588","volume":"36","author":"SM Goldinger","year":"2018","unstructured":"Goldinger SM, Lo S, Hassel JC, Forschner A, McKean MA, Zimmer L, et al. The utility of chemotherapy after immunotherapy failure in metastatic melanoma: a multicenter case series. J Clin Oncol. 2018;36:e21588\u2013e21588.","journal-title":"J Clin Oncol"},{"key":"1486_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fonc.2020.00070","volume":"10","author":"R Hadash-Bengad","year":"2020","unstructured":"Hadash-Bengad R, Hajaj E, Klein S, Merims S, Frank S, Eisenberg G, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma\u2014a retrospective study. Front Oncol. 2020;10:70.","journal-title":"Front Oncol"},{"key":"1486_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358\u201365.","journal-title":"Lancet"},{"key":"1486_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1357","volume":"16","author":"S Suissa","year":"2007","unstructured":"Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16:241\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1486_CR24","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.ejca.2013.12.015","volume":"50","author":"C Gaudy-Marqueste","year":"2014","unstructured":"Gaudy-Marqueste C, Archier E, Grob A, Durieux O, Loundou A, Richard M-A, et al. Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. Eur J Cancer. 2014;50:1120\u20134.","journal-title":"Eur J Cancer"},{"key":"1486_CR25","doi-asserted-by":"publisher","first-page":"e1442166","DOI":"10.1080\/2162402X.2018.1442166","volume":"7","author":"A Roger","year":"2018","unstructured":"Roger A, Finet A, Boru B, Beauchet A, Mazeron J-J, Otzmeguine Y, et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. OncoImmunology. 2018;7:e1442166.","journal-title":"OncoImmunology"},{"key":"1486_CR26","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/ijc.32934","volume":"147","author":"E Funck-Brentano","year":"2020","unstructured":"Funck-Brentano E, Baghad B, Fort M, Aouidad I, Roger A, Beauchet A, et al. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy. Int J Cancer. 2020;147:1707\u201314.","journal-title":"Int J Cancer"},{"key":"1486_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","volume":"15","author":"A Tesniere","year":"2008","unstructured":"Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15:3\u201312.","journal-title":"Cell Death Differ"},{"key":"1486_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"key":"1486_CR29","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med"},{"key":"1486_CR30","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/cancers11111699","volume":"11","author":"JY Kim","year":"2019","unstructured":"Kim JY, Lee KH, Kang J, Borcoman E, Saada-Bouzid E, Kronbichler A, et al. Hyperprogressive disease during anti-PD-1 (PDCD1) \/ PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers (Basel). 2019;11:1699.","journal-title":"Cancers (Basel)"},{"key":"1486_CR31","doi-asserted-by":"publisher","first-page":"TPS4590","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4590","volume":"35","author":"T Powles","year":"2017","unstructured":"Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, et al. Phase 3 KEYNOTE-361 trial: pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. J Clin Oncol. 2017;35:TPS4590\u2013TPS4590.","journal-title":"J Clin Oncol"},{"key":"1486_CR32","doi-asserted-by":"publisher","first-page":"TPS499","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS499","volume":"37","author":"MD Galsky","year":"2019","unstructured":"Galsky MD, Necchi A, Sridhar SS, Ogawa O, Ruscica D, Angra N, et al. A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC). J Clin Oncol. 2019;37:TPS499\u2013TPS499.","journal-title":"J Clin Oncol"},{"key":"1486_CR33","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328.","journal-title":"Lancet"},{"key":"1486_CR34","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242\u201350.","journal-title":"Clin Cancer Res"},{"key":"1486_CR35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","volume":"13","author":"AM Di Giacomo","year":"2012","unstructured":"Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13:879\u201386.","journal-title":"Lancet Oncol"},{"key":"1486_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","volume":"30","author":"J Vera Aguilera","year":"2020","unstructured":"Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, Kumar AB, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30:364\u201375.","journal-title":"Melanoma Res"},{"key":"1486_CR37","doi-asserted-by":"crossref","unstructured":"Crosby T, Fish R, Coles B, Mason M. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2000;CD001215.","DOI":"10.1002\/14651858.CD001215"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01486-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01486-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01486-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:04:08Z","timestamp":1657757048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01486-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9,28]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01486-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"14 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to French Law, this study abided by standard medical practices and did not require a written informed consent. However, consent was obtained orally from all patients. In addition, patients gave written informed consent to participate in national French prospective cohorts of advanced melanoma (MelBase: NTC028228202, RIC-Mel: NCT03315468, MelanCohort). The study was conducted according to the principles of the declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"CL: Pierre Fabre, Novartis, Bristol-Myers Squibb and MSD (C\/A). PS: Amgen, Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, and Novartis (C\/A). EFB: Pierre Fabre, Novartis, Bristol-Myers Squibb and MSD (C\/A). (C\/A) Consulting\/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights\/inventor\/patent holder; (SAB) Scientific advisory board.Authors\u2019 information (optional).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}